ADC Therapeutics SA Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent
ADC Therapeutics SA (ADCT) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent of $43.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent · last filed 2026-08-13
- ADC Therapeutics SA other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2026-06-30 was $43.00K, a 6.52% decline year-over-year.
- ADC Therapeutics SA other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2026-03-31 was $44.00K, a 4.76% increase year-over-year.
- ADC Therapeutics SA other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-12-31 was -$169.00K, a 118.39% decline year-over-year.
- ADC Therapeutics SA other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-09-30 was $47.00K, a 6.82% increase year-over-year.
- ADC Therapeutics SA other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2025 was -$33.00K, a 103.16% decline from fiscal 2024.
- ADC Therapeutics SA other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2024 was $1.04M, a 43.69% decline from fiscal 2023.
- ADC Therapeutics SA other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2023 was $1.85M.
- ADC Therapeutics SA other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2022 was -$4.12M.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 9 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.00K 10-Q · filed 2026-08-13 | $87.00K 10-Q · filed 2026-08-13 | -$82.00K derived: sum of 3 quarters · filed 2026-08-13 | -$35.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $44.00K 10-Q · filed 2026-05-04 | -$125.00K derived: sum of 2 quarters · filed 2026-05-04 | -$78.00K derived: sum of 3 quarters · filed 2026-05-04 | -$32.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$169.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$122.00K derived: sum of 2 quarters · filed 2026-03-10 | -$76.00K derived: sum of 3 quarters · filed 2026-08-13 | -$33.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $47.00K 10-Q · filed 2025-11-10 | $93.00K derived: sum of 2 quarters · filed 2026-08-13 | $136.00K 10-Q · filed 2025-11-10 | $1.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $46.00K 10-Q · filed 2026-08-13 | $88.00K 10-Q · filed 2026-08-13 | $1.01M derived: sum of 3 quarters · filed 2026-08-13 | $1.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $42.00K 10-Q · filed 2026-05-04 | $961.00K derived: sum of 2 quarters · filed 2026-05-04 | $1.00M derived: sum of 3 quarters · filed 2026-05-04 | $1.09M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $919.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $963.00K derived: sum of 2 quarters · filed 2026-03-10 | $1.04M derived: sum of 3 quarters · filed 2026-03-10 | $1.04M 10-K · filed 2026-03-10 |
| 2024-09-30 | $44.00K 10-Q · filed 2025-11-10 | $125.00K derived: sum of 2 quarters · filed 2025-11-10 | $125.00K 10-Q · filed 2025-11-10 | $1.86M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $81.00K 10-Q · filed 2025-08-12 | $81.00K 10-Q · filed 2025-08-12 | $1.82M derived: sum of 3 quarters · filed 2025-08-12 | $1.86M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $1.74M derived: sum of 2 quarters · filed 2025-05-14 | $1.77M derived: sum of 3 quarters · filed 2025-05-14 | $1.81M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.77M derived: sum of 2 quarters · filed 2025-03-27 | $1.81M derived: sum of 3 quarters · filed 2025-03-27 | $1.85M 10-K · filed 2025-03-27 |
| 2023-09-30 | $39.00K 10-Q · filed 2024-11-07 | $79.00K derived: sum of 2 quarters · filed 2024-11-07 | $118.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $40.00K 10-Q · filed 2024-08-06 | $79.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $39.00K 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | -$4.12M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |